SCHEMBL27415873

SCHEMBL27415873

Fc1ccc(-c2cnc(Cl)cc2F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
RPS6KA3 P51812 2/20 0.41
ADORA1 P30542 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
TDO2 P48775 1/20 0.38
PTGS2 P35354 3/20 0.38
PTGS1 P23219 1/20 0.36
KCNQ3 O43525 1/20 0.36
KCNQ2 O43526 1/20 0.36
KCNE1 P15382 1/20 0.36
KCNQ1 P51787 1/20 0.36
BACE1 P56817 1/20 0.36
MAPK14 Q16539 2/20 0.36
GCGR P47871 1/20 0.36
MAP4K4 O95819 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27415921 0.81 RPS6KA3 (0.46) NPC1RAB9AMEN1KMT2ARPS6KA3
SCHEMBL30919866 0.81 RPS6KA3 (0.44) NPC1RAB9AMEN1KMT2ARPS6KA3
SCHEMBL17506391 0.78 RPS6KA3 (0.39) NPC1RAB9AMEN1KMT2ARPS6KA3
SCHEMBL26120082 0.77 ADORA1 (0.50) NPC1RAB9AMEN1KMT2AADORA1
SCHEMBL26115858 0.77 RPS6KA3 (0.39) NPC1RAB9AMEN1KMT2ARPS6KA3
SCHEMBL1686082 0.75 TRPA1 (0.40) NPC1RAB9ARPS6KA3ADORA1SMN1; SMN2
SCHEMBL1875629 0.74 ABL1 (0.41) NPC1RAB9AMEN1KMT2ARPS6KA3
SCHEMBL1875628 0.74 MEN1 (0.37) NPC1RAB9AMEN1KMT2ARPS6KA3
SCHEMBL9931109 0.73 MAP4K4 (0.41) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL5778726 0.73 MAP4K4 (0.46) NPC1RAB9AMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208983-A1 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 VANDERBILT UNIVERSITY 2024-06-27 US disclosed
US-20240208983-A1 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 VANDERBILT UNIVERSITY 2024-06-27 US disclosed
WO-2022212818-A1 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 VANDERBILT UNIVERSITY (US) 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208983-A1 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 GRM2, GRM1, GRM3 NPC1 3153/4885RAB9A 2627/4885MEN1 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.